Schizophrenia Clinical Trials in St Louis, Missouri

6 studies are recruiting for schizophrenia in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. 52-week Open Label Safety-Tolerability Study

    Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Arch Clinical Trials, St Louis, Missouri
    Locations
    23 in total
    Run by
    LB Pharmaceuticals Inc.
  2. A Study of Brenipatide in Adult Participants With Schizophrenia

    The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

    Stage
    Phase 2
    Ages
    18 to 55
    Site
    Arch Clinical Trials, St Louis, Missouri
    Locations
    103 in total
    Run by
    Eli Lilly and Company
  3. Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

    The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Arch Clinical Trials LLC, St Louis, Missouri
    Locations
    16 in total
    Run by
    Novartis Pharmaceuticals
  4. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Arch Clinical Trials, St Louis, Missouri
    Locations
    13 in total
    Run by
    LB Pharmaceuticals Inc.
  5. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, St Louis, Missouri
    Locations
    57 in total
    Run by
    Neurocrine Biosciences
  6. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Vanda Investigational Site, St Louis, Missouri
    Locations
    22 in total
    Run by
    Vanda Pharmaceuticals

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.